In Vivo Dosimetry for Brachytherapy Study

Launched by EAST AND NORTH HERTFORDSHIRE NHS TRUST · Mar 3, 2025

Keywords

ClinConnect Summary

This clinical trial, titled "In Vivo Dosimetry for Brachytherapy Study," is focused on improving treatment for patients with prostate cancer and gynecological cancers through a method called brachytherapy, which involves placing small radioactive sources directly inside or near the tumor to deliver targeted radiation. The study aims to use special devices, known as in vivo dosimeters, to measure the radiation dose received by the patient during this treatment. This could help ensure that patients receive the right amount of radiation to effectively treat their cancer while minimizing side effects.

To participate in this study, individuals must be at least 18 years old and undergoing high-dose-rate brachytherapy with a specific radioactive material for either prostate cancer or certain gynecological cancers, such as cervical or endometrial cancer. Eligible participants should be in generally good health, as assessed by their performance status. If you join the trial, you can expect to have your radiation dose measured during your treatment, which could provide valuable information for improving future care. It's important to note that individuals with certain medical conditions or those who have had previous brachytherapy in the same area cannot participate.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged 18 years and above
• * Patients receiving HDR brachytherapy using iridium-192 (192Ir) radioactive source either as a monotherapy or in combination with external beam radiotherapy for:
• • 1. histologically/radiologically proven primary or locally recurrent prostate cancer
• • 2. locally advanced gynaecological malignancy in the primary and recurrent setting
• • primary cervix carcinoma (squamous, adenocarcinoma, adenosquamous) FIGO IB2-IVA
• • primary vulval FIGO I-IVA
• • primary vaginal FIGO I-IVA
• • primary endometrial cancer FIGO Stage I-IVA (not suitable for surgery)
• • endometrial cancer receiving adjuvant vaginal vault brachytherapy
• • recurrent cervix, vulval, vaginal or endometrial cancer suitable for brachytherapy as discussed in a regional gynae-oncology multidisciplinary meeting.
• • World Health Organisation (WHO) or Eastern Cooperative Oncology Group (ECOG) performance status 0-2
• Exclusion Criteria:
• • Previous brachytherapy exposure to the treatment site
• • Patients unable to give informed consent
• • Patients unable to have a regional or general anaesthetic
• • Patients with the following medical conditions: coagulopathies, history of another primary malignancy, known allergy or sensitivity to study materials; previous or current fistulae
• • Not able to understand the implications of participating in the study in English
• • Patients with recent (within the last 6 months) or currently participating in interventional research